Tags

Type your tag names separated by a space and hit enter

Anti-obesity drugs: a review about their effects and their safety.
Expert Opin Drug Saf. 2012 May; 11(3):459-71.EO

Abstract

INTRODUCTION

Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity.

AREAS COVERED

The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss.

EXPERT OPINION

Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.

Authors+Show Affiliations

University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Department of Internal Medicine and Therapeutics, P.le C. Golgi, 2 - 27100 Pavia, Italy. giuseppe.derosa@unipv.itNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22439841

Citation

Derosa, Giuseppe, and Pamela Maffioli. "Anti-obesity Drugs: a Review About Their Effects and Their Safety." Expert Opinion On Drug Safety, vol. 11, no. 3, 2012, pp. 459-71.
Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459-71.
Derosa, G., & Maffioli, P. (2012). Anti-obesity drugs: a review about their effects and their safety. Expert Opinion On Drug Safety, 11(3), 459-71. https://doi.org/10.1517/14740338.2012.675326
Derosa G, Maffioli P. Anti-obesity Drugs: a Review About Their Effects and Their Safety. Expert Opin Drug Saf. 2012;11(3):459-71. PubMed PMID: 22439841.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-obesity drugs: a review about their effects and their safety. AU - Derosa,Giuseppe, AU - Maffioli,Pamela, Y1 - 2012/03/23/ PY - 2012/3/24/entrez PY - 2012/3/24/pubmed PY - 2012/8/15/medline SP - 459 EP - 71 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 11 IS - 3 N2 - INTRODUCTION: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. AREAS COVERED: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. EXPERT OPINION: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/22439841/Anti_obesity_drugs:_a_review_about_their_effects_and_their_safety_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.2012.675326 DB - PRIME DP - Unbound Medicine ER -